Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein, CF Summary
Accession # NP_001265355.2
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
When Recombinant Human Apolipoprotein E3 (Catalog # 4144-AE) is immobilized at 5 µg/mL, 100 µL/well, the concentration of Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera (Catalog #10429-T4) that produces 50% of the optimal binding response is approximately 0.8-5 µg/mL.
2 μg/lane of Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein (Catalog # 10429-T4) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-75 kDa and 110-150 kDa, respectively.
ILT3, also known as LILRB4, CD85k, and LIR5, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation (1). Mature human ILT3 consists of an extracellular domain (ECD) with two Ig-like domains, a transmembrane segment, and a cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM) (2). The mature ECD of human ILT3 shares 44% amino acid identity with mouse ILT3. Alternative splicing of human ILT3 generates an isoform that lacks the first ITIM and a secreted isoform that circulates in the serum of cancer patients (3, 4). ILT3 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC) (2, 5, 6). Ligation of ILT3 triggers ITIM-mediated inhibition of cell-activating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection (2, 4, 7, 8). Soluble ILT3 induces the differentiation of CD8+ T suppressor cells (Ts) that can inhibit the effector functions of CD4+ Th cells and CD8+ CTL (4, 7, 9). In turn, CD8+ Ts cells induce ILT3 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC (5, 6, 8, 10, 11). Recently, a novel anti-LILRB4 CAR-T Cell was been used to treat monocytic acute myeloid leukemia in humanized hematopoietic-reconstituted mice models (12).
- Vlad, G. et al. (2010) Int. Rev. Immunol. 29:119.
- Cella, M. et al. (1997) J. Exp. Med. 185:1743.
- Heinzmann, A. et al. (2000) Eur. J. Immunogenet. 27:121.
- Suciu-Foca, N. et al. (2007) J. Immunol. 178:7432.
- Gleissner, C.A. et al. (2007) Eur. J. Immunol. 37:177.
- Manavalan, J.S. et al. (2004) Int. Immunol. 16:1055.
- Vlad, G. and N. Suciu-Foca (2012) Exp. Mol. Pathol. 93:294.
- Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
- Vlad, G. et al. (2006) Int. Immunopharmacol. 6:1889.
- Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
- Brenk, M. et al. (2009) J. Immunol. 183:145.
- John, S. et al. (2018) Mol. Ther. 26:2487.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image